Robert Burns

Chair of the Board

Elected in: 2017
Born: 1947
Independent in relation to major shareholders: Yes

Robert Burns is a Board Director of Circio (formerly Targovax) and has been CEO of three companies active in research and development of antibodies (Celldex, Affitech, and 4-Antibody AG). Previously, he has been Chairman of Haemostatix, up until the successful divestment to Ergomed. Robert has previously held leading positions in commercial operations and business development at Ludwig Cancer Research, Oxford Glycosciences, British Biotechnology, Applied bioTechnology, and Corning Incorporated. Robert holds a PhD in chemistry from the University of  Birmingham.

Board Committee: Chair of the Remuneration Committee and member of the Audit Committee and Commercialization Committee.

Holdings in Affibody: 30,338 shares and 40,000 options.

Mathias Uhlén

Board Director

Elected in: 1998 (Affibody AB)
Born: 1954
Independent in relation to major shareholders: Yes

Mathias Uhlén is one of the co-founders of Affibody and Professor in biotechnology at KTH Royal School of Technology and Guest Professor at the Karolinska Institute. He is the Program Director of the Human Protein Atlas (HPA) project, which is financed by the Knut and Alice Wallenberg foundation. Mathias is Chairman of the Board of ScandiBio Therapeutics AB, ScandiEdge Therapeutics AB, MU Bioteknik AB, Antibodypedia AB and ProteomEdge AB and Board Director of Atlas Antibodies AB, NorthX, Vetenskapsrådet and Intervacc (publ).

Holdings in Affibody: 905,719 shares (including related companies) and 40,000 options.

Jonathan Knowles

Board Director

Elected in: 2011
Born: 1947
Independent in relation to major shareholders: Yes

Jonathan Knowles is a Visiting Professor in Personalized Health at the Finnish Institute for Molecular Medicine at the University of Helsinki and a Visiting Professor at the University of Oxford. He is currently a board member of Caris Life Sciences, a major US based cancer diagnostics company, Board Director of Immunophotonics Inc. an innovative immune oncology company. He was the founding chairman of the Innovative Medicines Initiative, one of the largest public private partnerships in the world, and founding chairman of Genomics England Access Committee. He is the former Head of Group Research of the Roche Group and full member of the Roche Group executive committee. Additionally, Jonathan was a Board Director of Genentech, USA, for twelve years, and of Chugai Pharmaceuticals, Japan, for seven years.

Holdings in Affibody: 17,305 shares and 40,000 options.

Jakob Lindberg

Board Director

Elected in: 2011
Born: 1972
Independent in relation to major shareholders: Yes

Jakob Lindberg is Senior Scientific Advisor at Oncopeptides and Board Director of Camurus. He was previously a board member at Atlas Antibodies and Alligator Bioscience, and CEO of Oncopeptides. Jakob started his career as an analyst at Merrill Lynch in London and then became a consultant with McKinsey, followed by a period as CEO and co-founder of Cellectricon. Jakob holds a licentiate of medical science in molecular immunology and a MSc degree from the Karolinska Institute, as well as a BA in economics and administration from Stockholm University.

Board Committee: Member of the Remuneration Committee.

Holdings in Affibody: 40,000 options.

Filippa Stenberg

Board Director

Elected in: 2025
Born: 1985
Independent in relation to major shareholders: No

Filippa Stenberg is currently Managing Director at Patricia Industries, part of Investor AB. Since 2021 she has served on the board of Swedish Orphan Biovitrum AB (Sobi), where she also is a member of the audit committee. She has previously worked as Chief Strategy Officer at Atlas Antibodies, Investment Manager at Investor AB, and analyst at Swedbank. She has a MSc in business and economics from the Stockholm School of Economics.

Board Committee: Member of the Audit Committee, Remuneration Committee and Commercialization Committee.

Holdings in Affibody: No holdings.

Gillian M Cannon

Board Director

Elected in: 2019
Born: 1963
Independent in relation to major shareholders: Yes

Gillian M Cannon has over 30 years of experience in the pharmaceutical industry, where she has served in leadership roles at multiple prominent global pharmaceutical companies including Merck and Co. Inc., UCB Inc. and Otsuka Pharmaceuticals. In 2018, Gillian joined Roivant Sciences, serving initially as President for Alyvant and subsequently as Head of Commercial Innovation for Roivant until April 2024. Gillian serves as a Board Director for Edinburgh Innovations, Corcept Therapeutics Inc., Our Future Health, Xenon Pharmaceuticals and CoSyne Therapeutics. She holds a PhD in Health Administration from Temple University, an MBA (concentration in marketing), and an undergraduate degree in Biochemistry from University of Edinburgh.

Board Committee: Chair of the Commercialization Committee.

Holdings in Affibody: 40,000 options.

Rachel Humphrey

Board Director

Elected in: 2025
Born: 1961
Independent in relation to major shareholders: Yes

Rachel Humphrey as spent over 25 years in drug development. Rachel is currently the President and Founding CEO of Normunity. Highlights of her career include oversight of the development of Yervoy® (ipilimumab; BMS), Imfinzi® (durvalumab; AZ), and Nexavar® (sorafenib;Bayer). She has held Chief Medical Officer roles at Mirati, CytomX Therapeutics and Black Diamond Therapeutics. She previously served as an independent member of the Board of Directors at CytomX Therapeutics and Xilio Therapeutics, and currently serves on the Board of Directors of Pyxis Therapeutics, Sporos Bioventures, and Voro Therapeutics. Her education includes a BA from Harvard, MD at Case Western Reserve, Internal Medicine at Johns Hopkins, and Oncology at the National Cancer Institute.

Holdings in Affibody: No holdings.

Anders Martin-Löf

Board Director

Elected in: 2021
Born: 1971
Independent in relation to major shareholders: Yes

Anders Martin-Löf is a Board Director of Cantargia. He has extensive experience as CFO in companies listed on the Stockholm stock exchange and is the CFO of BioArctic AB. He has previously been CFO at Oncopeptides, Wilson Therapeutics, and RaySearch Laboratories. He has also been Head of Investor Relations and held various positions in business development at Swedish Orphan Biovitrum. Anders holds an MSc in Engineering Physics from the Royal Institute of Technology, and a BSc in Business Administration and Economics from Stockholm University.

Board Committee: Chair of the Audit Committee.

Holdings in Affibody: 40,000 options.

Michael Monaghan

Board Director
Employee Representative

Elected in: 2022
Born: 1985
Independent in relation to major shareholders: Yes

Michael Monaghan serves on the Board of Directors as an employee representative. He is currently employed as Business Controller at Affibody AB. He has previous experience in controlling, demand planning, and financial analysis as Finance Manager and Analyst at the Nordic affiliates of Abbott Laboratories, Abbvie, and Mylan. Michael has also worked as R&D Controller and in the R&D department as Portfolio Manager at Swedish Orphan Biovitrum (Sobi). Michael received a BA in Business Administration and German from Towson University.

Holdings in Affibody: 5,000 options.

Rezan Güler

Board Director
Employee Representative

Elected in: 2025
Born: 1990
Independent in relation to major shareholders: Yes

Rezan Güler serves on the Board of Directors as an employee representative. He is currently employed as Senior Scientist in Protein Engineering at Affibody AB. He holds an MSc in Medical Biotechnology and a PhD in Biotechnology from the KTH Royal Institute of Technology, Stockholm.

Holdings in Affibody: 5,000 options.